1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Alzheimer’s Disease: Update Bulletin #2 [April 2018]

Alzheimer’s Disease: Update Bulletin #2 [April 2018]

  • April 2018
  • ID: 5438892
  • Format: PDF
  • By Firstword Pharma

Summary

This edition presents key opinion leader (KOL) views on recent developments in the Alzheimer’s Disease (AD) market. Topics covered include; results from the Phase IIa clinical study of EIP Pharma’s neflamapimod (VX-745); an overview of data for the Phase Ib/IIa COG010 study of Cognition Therapeutics’ Elayta (CT1812); the conclusion of the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial investigating plasma exchange with Grifols’ human albumin solution, Albutein, combined with intravenous immunoglobulin (IVIG).

Business Questions
• How successful do KOLs think that p38 MAP kinase alpha inhibition could prove to be as an approach for treating AD?
• Do the results from the Phase IIa study with neflamapimod confirm its potential activity as a treatment for AD?
• How important will the REVERSE-SD study be in terms of providing a better understanding of neflamapimod’s role as an AD therapy?
• Do KOLs think that Elayta’s mechanism of action is compatible with it having a neuroprotective role in patients with AD?
• Which types of patient are most likely to benefit from treatment with Elayta?
• How do KOLs perceive plasma exchange as a method for reducing the beta-amyloid load in the brains of patients with AD?
• Which factors are likely to influence the extent to which plasma exchange with Albutein/IVIG is utilised as a treatment for AD?
• How do KOLs rate the chances of the AMBAR trial meeting its primary endpoint and plasma exchange therapy with Albutein/IVIG being successfully marketed?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer’s and Parkinson’s Diseases

Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer’s and Parkinson’s Diseases

  • $ 4950
  • August 2019

At present, only a few therapies are available with relatively low success.Both, the clinical and the scientific communities are critically devoted to develop new therapeutic approaches to treat and diagnose ...

Emerging Therapeutics for Neurodegenerative Diseases Part II: Huntington’s Disease and Amyotrophic Lateral Sclerosis (HD & ALS)

Emerging Therapeutics for Neurodegenerative Diseases Part II: Huntington’s Disease and Amyotrophic Lateral Sclerosis (HD & ALS)

  • $ 4950
  • September 2019

At present, only a few therapies are available with relatively low success.Both, the clinical and the scientific communities are critically devoted to develop new therapeutic approaches to treat and diagnose ...

Hepatic Encephalopathy - Pipeline Review, H2 2019

Hepatic Encephalopathy - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Hepatic Encephalopathy - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2019, provides ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on